Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „when“
Suchtreffer
Begriffe & Kennungen
Braftovi · 4.8 · When encorafenib was used at a dose of 300 mg once daily in combination with binimetinib 45 mg twice daily (Co
Eintrag öffnenBridion · 4.5 · Interactions due to the lasting effect of rocuronium or vecuronium: When medicinal products which potentiate n
Eintrag öffnenBrilique · 4.5 · 52 monitoring is recommended when giving narrow therapeutic index P-gp dependent medicinal products like digox
Eintrag öffnenBrintellix · 4.5 · 25 CYP3A4 inhibitors and CYP2C9, and CYP2C19 inhibitors When vortioxetine was co-administered following 6 days
Eintrag öffnenBrintellix · 4.5 · 6 CYP2D6 inhibitors The exposure to vortioxetine increased 2.3-fold for area under the curve (AUC) when vortio
Eintrag öffnenBrintellix · 4.5 · CYP2D6 inhibitors The exposure to vortioxetine increased 2.3-fold for area under the curve (AUC) when vortioxe
Eintrag öffnenBrintellix · 4.5 · CYP3A4 inhibitors and CYP2C9, and CYP2C19 inhibitors When vortioxetine was co-administered following 6 days of
Eintrag öffnenBrintellix · 4.5 · Cytochrome P450 inducers When a single dose of 20 mg vortioxetine was co-administered following 10 days of rif
Eintrag öffnenBrintellix · 4.5 · Cytochrome P450 inducers When a single dose of 20 mg vortioxetine was co-administered following 10 days of rif
Eintrag öffnenBriumvi · 4.5 · When initiating Briumvi after an immunosuppressive therapy, or when initiating an immunosuppressive therapy af
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluco
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluco
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluco
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Strong enzyme inducing AEDs Brivaracetam plasma concentrations are decreased when coadministered with strong e
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Strong enzyme inducing AEDs Brivaracetam plasma concentrations are decreased when coadministered with strong e
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Strong enzyme inducing AEDs Brivaracetam plasma concentrations are decreased when coadministered with strong e
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.8 · 46 No specific pattern of adverse event (AE) was identified in children from 1◦month to < 4◦years of age when
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.8 · No specific pattern of adverse event (AE) was identified in children from 1◦month to < 4◦years of age when com
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.8 · No specific pattern of adverse event (AE) was identified in children from 1◦month to < 4◦years of age when com
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnen